Mylan Receives EU Marketing Approval for Adalimumab Biosimilar “Hulio”
Shots:
- Hulio’s EU Marketing Approval is followed after CHMP approval that demonstrated analytical- functional- clinical and immunogenicity data similar to AbbVie’s Humira
- In 2018- Kyowa and Mylan signed an agreement for exclusive commercialization right of Hulio in EU- and is expect to launch on or after 16 Oct- 2018
- Adalimumab is an injectable- biologic medication inhibits Tumour Necrosis Factor (TNF)- which is indicated for autoimmune diseases such as rheumatoid arthritis- plaque psoriasis- crohn's disease and ulcerative colitis
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
